MMR deficiency and POLE/POLD1 mutations are correlated with hypermutated/MSI and with ultra-mutator phenotypes, respectively6, and have gained interest as positive predictors of immunotherapy response7–10. The gene discussed is POLE; the disease is mismatch repair cancer syndrome 1.